MiNK Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

MiNK Therapeutics CEO'su Jen Buell, Feb2021 tarihinde atandı, in görev süresi 3.75 yıldır. in toplam yıllık tazminatı $ 2.81M olup, şirket hissesi ve opsiyonları dahil olmak üzere 16.1% maaş ve 83.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.59% ine doğrudan sahiptir ve bu hisseler $ 168.09K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.3 yıl ve 5.5 yıldır.

Anahtar bilgiler

Jen Buell

İcra Kurulu Başkanı

US$2.8m

Toplam tazminat

CEO maaş yüzdesi	16.1%
CEO görev süresi	3.8yrs
CEO sahipliği	0.6%
Yönetim ortalama görev süresi	3.3yrs
Yönetim Kurulu ortalama görev süresi	5.5yrs

Son yönetim güncellemeleri

Recent updates

MiNK Therapeutics (NASDAQ:INKT) Will Have To Spend Its Cash Wisely

Oct 26

Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Deliver On Growth Plans?

Jun 28

CEO Tazminat Analizi

Jen Buell'un ücretlendirmesi MiNK Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$14m
Jun 30 2024	n/a	n/a	-US$17m
Mar 31 2024	n/a	n/a	-US$21m
Dec 31 2023	US$3m	US$451k	-US$22m
Sep 30 2023	n/a	n/a	-US$25m
Jun 30 2023	n/a	n/a	-US$26m
Mar 31 2023	n/a	n/a	-US$26m
Dec 31 2022	US$4m	US$424k	-US$28m
Sep 30 2022	n/a	n/a	-US$26m
Jun 30 2022	n/a	n/a	-US$34m
Mar 31 2022	n/a	n/a	-US$34m
Dec 31 2021	US$3m	US$233k	-US$30m
Sep 30 2021	n/a	n/a	-US$26m
Jun 30 2021	n/a	n/a	-US$18m
Mar 31 2021	n/a	n/a	-US$16m
Dec 31 2020	US$917	n/a	-US$16m

Tazminat ve Piyasa: Jen 'nin toplam tazminatı ($USD 2.81M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 647.72K ).

Tazminat ve Kazançlar: Jen 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Jen Buell (49 yo)

3.8yrs

Görev süresi

US$2,807,439

Tazminat

Dr. Jennifer S. Buell, also known as Jen, Ph.D. is a Director at Agenus Inc since June 11, 2024. She has been Independent Director at Protagenic Therapeutics, Inc. since July 18, 2020. Dr. Buell served as...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Garo Armen	Executive Chairman	7.3yrs	US$344.32k	4.37% $ 1.3m
Jennifer Buell	President	3.8yrs	US$2.81m	0.59% $ 168.1k
Christine Klaskin	Treasurer	7.3yrs	US$29.62k	0.14% $ 40.3k
Robert Foster	Director of Legal & Business Affairs	less than a year	Veri yok	Veri yok
Joy Zhou	Vice President & Head of CMC	2.8yrs	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: INKT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Garo Armen	Executive Chairman	7.3yrs	US$344.32k	4.37% $ 1.3m
Jennifer Buell	President	3.8yrs	US$2.81m	0.59% $ 168.1k
Robert Stein	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
Ulf Wiinberg	Independent Director	7.3yrs	US$106.95k	0.97% $ 277.8k
Manuel Hidalgo	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
Brian Corvese	Independent Director	7.3yrs	US$154.75k	0.97% $ 277.7k
Barbara Ryan	Independent Director	3.2yrs	US$154.25k	0.26% $ 75.6k
Mark Exley	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
Marcela Maus	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
Jenny Gumperz	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
Peter Behner	Independent Director	3.6yrs	US$111.45k	0.23% $ 65.5k
Lydia Lynch	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok

5.5yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: INKT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.5 yıldır).

MiNK Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

MiNK Therapeutics, Inc. Announces Appointment of Dr. Robert Kadlec to Board of Directors

MiNK Therapeutics, Inc. Appoints Marc Van Dijk as Scientific Advisory Board Member, Effective from November 15, 2024

Insufficient new directors

MiNK Therapeutics, Inc. Announces Resignation of as Director

Executive Chairman recently bought US$95k worth of stock

MiNK Therapeutics, Inc., Annual General Meeting, Jun 08, 2022

Recent updates

Price target decreased by 20% to US$6.67

MiNK Therapeutics, Inc. to Report Q3, 2024 Results on Nov 14, 2024

MiNK Therapeutics, Inc. Announces Data from Two Poster Presentations at Society for Immunotherapy of Cancer's 39th Annual Meeting in Houston, Texas

MiNK Therapeutics, Inc. Announces Appointment of Dr. Robert Kadlec to Board of Directors

MiNK Therapeutics, Inc. Appoints Marc Van Dijk as Scientific Advisory Board Member, Effective from November 15, 2024

Insufficient new directors

MiNK Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Minimum Value of Listed Securities

MiNK Therapeutics Provides Non-Compliance Update with the Nasdaq's Minimum Bid Price Requirement

New major risk - Financial position

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

MiNK Therapeutics, Inc. to Report Q2, 2024 Results on Aug 13, 2024

New minor risk - Shareholder dilution

MiNK Therapeutics, Inc. Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

MiNK Therapeutics, Inc. announced that it has received $5.8 million in funding

MiNK Therapeutics, Inc. announced that it expects to receive $5.8 million in funding

MiNK Therapeutics, Inc. to Report Q1, 2024 Results on May 14, 2024

New minor risk - Share price stability

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

MiNK Therapeutics, Inc. to Report Q4, 2023 Results on Mar 21, 2024

MiNK Therapeutics Receives Letter from Nasdaq Notifying the Company Failed to Comply with the $1 Minimum Bid Price

MiNK Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study for agenT-797 in Second Line Gastroesophageal Cancer

Mink Therapeutics' Agent-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications

Mink’S Agent-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

MiNK Therapeutics, Inc. Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

MiNK Therapeutics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

MiNK Therapeutics (NASDAQ:INKT) Will Have To Spend Its Cash Wisely

MiNK Therapeutics, Inc. Announces Resignation of as Director

Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Deliver On Growth Plans?

Price target increased by 12% to US$7.00

Executive Chairman recently bought US$95k worth of stock

Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Invest In Growth?

Price target decreased to US$7.75

Mink Therapeutics, Inc. Presents Clinical Data At Sitc 2022 Showcasing Inkt Cell Therapy Pipeline

MiNK Therapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

MiNK Therapeutics GAAP EPS of -$0.18

MiNK Therapeutics GAAP EPS of -$0.18

MiNK Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

MiNK Therapeutics, Inc.(NasdaqCM:INKT) dropped from Russell 2500 Value Index

MiNK Therapeutics A Bargain For Potential Cell Therapies

We're Hopeful That MiNK Therapeutics (NASDAQ:INKT) Will Use Its Cash Wisely

MiNK Therapeutics, Inc., Annual General Meeting, Jun 08, 2022

MiNK Therapeutics, Inc. to Report Q4, 2021 Results on Mar 18, 2022

MiNK Therapeutics Announces Patients Dosed with Agent-797 iNKT Cell Therapy in Solid Tumor Cancers

High number of new directors

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş